Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 18,959 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $25.77, for a total value of $488,573.43. Following the completion of the transaction, the chief financial officer now directly owns 132,578 shares of the company's stock, valued at approximately $3,416,535.06. This trade represents a 12.51 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Oluyemi Okupe also recently made the following trade(s):
Shares of HIMS stock traded up $1.40 on Monday, hitting $27.60. The stock had a trading volume of 10,968,314 shares, compared to its average volume of 10,082,213. The business has a 50 day moving average of $25.78 and a 200 day moving average of $21.26. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02. The stock has a market cap of $6.03 billion, a price-to-earnings ratio of 62.73 and a beta of 1.25.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.04) EPS. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
A number of analysts have recently commented on the company. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a research note on Monday, December 2nd. TD Cowen reissued a "buy" rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research report on Wednesday, November 6th. Piper Sandler restated a "neutral" rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an "overweight" rating and a $42.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $22.80.
Read Our Latest Report on HIMS
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its position in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC raised its holdings in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after purchasing an additional 3,507 shares during the period. Van ECK Associates Corp purchased a new position in Hims & Hers Health in the second quarter valued at approximately $111,000. CWM LLC grew its holdings in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Finally, Quarry LP increased its position in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company's stock worth $113,000 after buying an additional 2,913 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.
Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.